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Abstract: Several studies suggest that, on the basis of life expectancy (LE) regressions, new 
pharmaceutical drugs are responsible for some of the marked gains in LE observed over the last 50 
years. We critically appraise these studies. We point out several modeling issues, including 
disentangling the contribution of new drugs from advances in disease management, changes in the 
distribution of health care and other confounding factors. We suggest that the studies estimates of 
pharmaceutical productivity are implausibly high. Some of the models have very large forecast 
errors. Finally, the models that we replicated were found to be sensitive to seemingly innocuous 
changes in specification. We conclude that it is difficult to estimate the bio-medical determinants of 
LE using aggregate data. Analyses using individual level data or perhaps disease specific data will 
likely produce more compelling results.  
 
JEL Classifications: I12, I18  
Keywords: pharmaceuticals, life expectancy, health production, treatment effects 
 
Résumé: Plusieurs études suggèrent, en se basant sur des analyses multivariées de l’espérance 
de vie (EV), que l’arrivée de nouveaux produits pharmaceutiques soit responsable des gains de 
l’EV observés au cours des cinquante dernières années. Nous évaluons ces études en portant un 
regard critique. Nous avons mis en évidence plusieurs problèmes de modélisation. Par exemple, 
nous tentons de démêler la contribution liée à l’arrivée de nouveaux médicaments, de celle liée aux 
progrès en matière de gestion de la maladie, aux changements de la répartition des soins de santé 
ainsi que d’autres facteurs de confusion. Nous pensons que les estimations élevées de la 
productivité pharmaceutique présentées dans ces études sont fort peu plausibles. Certains 
modèles souffrent d’erreurs de prédiction importantes. Finalement, les modèles que nous avons 
répliqués sont sensibles à des variations en apparence anodines de leurs spécifications. Nous 
arrivons à la conclusion qu’il est difficile d’évaluer les déterminants bio-médicaux de l’EV en 
s’appuyant sur des données agrégées. Des analyses reposant sur des données individuelles ou 
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Life expectancy (LE) gains in many developed countries since WWII have been dramatic.  In Canada, for 
instance, LE at birth increased by about 11 years over the period 1950-2002, from 70.8 to 82.1 years for 
females and from 66.3 to 77.2 years for males (Beaudet, Tully and St-Arnaud 2005).  What has caused 
these recent LE increases?  Cutler, Deaton and Lleras-Muney (2006) point to advances in medical 
technology.  There is a growing body of evidence that new pharmaceutical drugs, in particular, are 
responsible for some of this LE increase.  This evidence comes from several sources: (i) clinical trials of 
new drugs, (ii) studies of trends in disease prevalence, and (iii) econometric LE models.  As examples: (i) 
clinical trials indicate that drugs can help prevent heart attack, stroke and heart failure, which are 
among the leading causes of death and disability (Welsfeldt and Zleman 2007); (ii) Lichtenberg (2003) 
has shown that the introduction of drugs for HIV-AIDs coincided with a dramatic reduction in mortality 
from the disease; and (iii) Lichtenberg (2004), Crémieux, Meilleur, Ouellette et al. (2005) (hereafter 
CMO), Frech and Miller (2004), and Shaw, Horrace, and Vogel (2005) (hereafter Shaw) have estimated 
the LE gain from drug spending and new drug launches.   
 
The econometric LE models suggest that drugs are remarkably effective.  Based on annual U.S. time-
series data on LE at birth, health expenditure, and new molecular entities (NMEs) approved each year 
during the period 1960–2001, Lichtenberg estimates that an additional year of life expectancy can be 
purchased for US$ 926 (1982 dollars) in per capita pharmaceutical research and development (R&D) 
expenditure, which is cheap compared to his estimated cost of buying a life year using public health 
expenditure ($9,640).  Using annual data on LE, drug and other types of health care spending in each of 
the ten Canadian provinces over the period 1981-1998, CMO estimate remarkably large drug 
expenditure-LE elasticities.  For instance, a one percent increase in private drug expenditure was found 
to increase male LE at birth by 0.015%.  Evaluating this response at sample means, this estimate implies 
that one more year of life expectancy can be had for additional per capita drug expenditure of only 
CDN$ 186 (1997 dollars).  This is a bargain: consensus estimates of the value of a life year are orders of 
magnitude larger (Viscusi and Aldy 2003).  Shaw, and Frech and Miller provide corroborating evidence.   
Shaw regressed LE in 19 OECD countries in 1997 on country-wide drug spending 12 years earlier and a 
battery of control variables; he estimates that male LE at age 40 increases by 1 year for every $175 
increase in drug spending.  Frech and Miller regressed ‘disability adjusted’ LE in 18 OECD countries in 
1999 on drug spending in 1990 and several control variables; their estimates imply that male disability 
adjusted LE at birth increases by 1 year for every $186 increase in drug spending.    
 
These results, taken at face value, have important health policy implications.  Indeed, Lichtenberg 
concludes that “increased development of new drugs may be a more cost-effective way of increasing life 
expectancy than increased public health expenditure.”  In other words, governments seeking to improve 
population health should realign spending priorities, reducing subsidies for physician and hospital 
services and increasing subsidies of pharmaceutical R&D.  The other studies do not appraise the value of 
medical R&D per se, but provide evidence that drugs are among the most cost effective forms of health 
care.   
 
Before governments act on these recommendations, it seems prudent to critically appraise these 
econometric analyses and ensure that the results standup upon re-examination of the data.  This is 
precisely what we attempt to do in this paper.  We point to several questionable assumptions 
underlying these empirical analyses, assess the plausibility of the estimates and re-analyze the data 
using what we feel are more appropriate econometric methods to see if the results stand up. 3  
 
The previous studies 
 
All four studies estimate LE ‘production functions’, although they take different approaches, both in the 
models estimated and the data used.  The years of LE produced depends on both the amounts of 
productive inputs used and the technology that converts these inputs into LE outputs.  Lichtenberg 
estimates the contribution of both medical technology (measured using the number of NMEs approved 
for use in the US each year) and the amounts of medical care and other inputs on LE at birth, whereas 
the others estimate the contribution of productive inputs alone.  Lichtenberg includes in his models 
lagged real per capita (RPC) health care expenditures, and in some of the models he considers, RPC 
gross domestic product (GDP) and cigarette consumption as well.  CMO consider a larger set of inputs.  
They model sex-specific LE, both LE at birth and at age 65, as a function of contemporaneous RPC public 
and private drug expenditures, RPC expenditures on other health services, various ‘life style’ factors 
(RPC expenditures on: food and non-alcoholic beverages, alcohol, and tobacco), RPC GDP and regional 
fixed effects.  They also model sex-specific infant mortality rates using the same covariates.  Shaw 
models sex-specific LE, at age 40, 60 and 65 in 1997 as a function of a set of covariates similar to those 
that CMO considered, except that Shaw used the 12 or 15 year lags of these covariates.  Frech and Miller 
model sex-specific disability adjusted LE (DALE) at birth and at age 60 in 1999 as a function of 1990 
values of RPC drug expenditures, RPC expenditures on other health services, alcohol consumption, and 
rates of smoking and obesity. 
 
 
Problems with the previous analyses 
 
Functional form issues 
 
All studies assume Cobb-Douglas LE production:  
 
?𝐸 = 𝐴?   𝑥𝑘
𝗽𝑘
𝑘                     (1) 
 
or in logs: 
 
ln?𝐸 = ?ln𝐴 +   𝗽𝑘 ln𝑥𝑘 𝑘                    (1A) 
 
where 𝐴 is the level of technology, 𝑥𝑘 is the level of the 𝑘th input, and  and the 𝑘 are unknown 








                       (2) 
 
Because the marginal productivities (2) depend on LE, they depend on the levels of all inputs and the 
existing technology.  While this model is plausible, it is somewhat restrictive.  It implies that the optimal 
mix of inputs does not depend on the scale of LE production.  One might question whether the 
restrictions inherent in (2) are consistent with the data and if not, how they can be relaxed.  That being 
said, the paucity of observations available – especially in the analyses of OECD countries – requires that 
a lot of structure be placed on the model if estimates are to be produced with reasonable precision. 
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A second concern relates to the separability of the ‘inputs’ from the ‘technology’ in the empirical LE 
production models.  The health care spending inputs considered in these models are not the 
homogenous inputs of the textbook production function because they embody – to varying degrees, 
depending on the input – the current technology.  This is especially true of drugs.  A dollar spent on 
drugs now likely yields more health gain than the (inflation adjusted) dollar spent in 1960, when the 
scope and effectiveness of drugs was much more limited.  This presents a modeling problem: it is 
difficult to neatly partition the role of technology and inputs in the empirical model.  In Lichtenberg’s LE 
model, the influence of pharmaceutical technology is reflected in both the number of NMEs approved 
and total health care spending (which includes as a component pharmaceuticals spending).   
 
There is one final yet important modeling issue.  CMO specify LE to be a function of current health care 
expenditures, when it seems plausible that health care spending might affect LE only after some time 
has elapsed.  The other investigators, recognizing this, use lagged health care expenditures in their LE 
models. 
 
Identification of pharmaceutical productivity   
 
All studies estimate parameters using least squares (LS).  For LS to be unbiased, covariates must be 
uncorrelated with variation in the outcome variable not explained by the model; the unexplained health 
determinants are captured in the model’s ‘error term’.  Yet it is unlikely that this condition is satisfied in 
the empirical LE models, for several reasons.  First, it is possible that health care inputs are endogenous:  
Governments and individuals alike may increase health care spending in regions/years in which age-
specific death rates are particularly high.  Lichtenberg’s econometric specification overcomes this: He 
uses lagged health care spending (and lagged new drug introductions) to at once overcome issues of 
endogeneity and allow health inputs to affect LE only after a lag, which seems more sensible that forcing 
all effects to be contemporaneous.  Shaw uses covariates lagged 12 or 15 years; Frech and Miller use 
covariates lagged 9 years.  As mentioned earlier, CMO’s specification is susceptible to this criticism.   
 
Second, model covariates that are measured with error will induce correlation between the 
mismeasured covariate and the error term.  Several covariates are mismeasured: CMO had to 
interpolate the values of alcohol, tobacco and dietary intake variables for a number of years.  Frech and 
Miller, CMO and Shaw measured drug consumption using inflation-adjusted nominal drug expenditure.  
But this is a very noisy measure of drug input – larger inflation-adjusted expenditures do not necessarily 
translate into longer LE, for several reasons.  One reason is that this expenditure variation could reflect 
differences in the vintage composition of drug use (with some provinces using a proportionately larger 
share of more recently introduced and more costly drugs), and the quantities used of drugs of all 
vintages.  Two provinces with identical drug spending – with one using lots of older, less productive but 
cheaper drugs and the other using a smaller amount of newer drugs – might therefore achieve different 
health outcomes.  Variation in inflation-adjusted drug spending might also reflect variation in other 
factors unrelated to ‘drug input’, including: 
 
  payments to drug wholesalers and pharmacies   
  waste: drugs dispensed but not taken as recommended (i.e. drug non-compliance), or the use of 
expensive drugs when less costly drugs work equally well (Morgan 2001).   
  use of drugs that affect primarily morbidity not mortality (Shaw, Horrace and Vogel 2005)  5  
 
  noise in the index used to adjust for drug price differences (which CMO never described), so that 
some of the variation in inflation-adjusted drug spending might actually reflect drug price 
differences.    
 
Shaw, and Frech and Miller face the same measurement issues as do CMO plus the problem of 
reconciling drug spending denominated in different currencies and collected using different accounting 
standards (Gerdtham and Jonsson, 2000).  Lichtenberg’s econometric specification overcomes these 
difficulties.  Implicitly he uses new drug introductions as an instrument for drug expenditures.  Instead of 
using instrumental variables estimation of a ‘structural’ model, however, he estimates a reduced form 
model; that is, he regresses LE on new drug introductions. 
 
Third, both LE and drug spending/new drug launches could be correlated with omitted variables, and 
these omitted variables would be contained in the error term.  The list of suspects includes the state of 
surgical, diagnostic, disease management and other non-pharmaceutical medical technologies that are 
not explicitly embodied in the health care spending variables.  Certainly, there have been important 
innovations in non-pharmaceutical medical innovation (Fuchs and Sox 2001) and these advances are 
often complementary to advances in pharmacotherapy.   The management of diabetes is a good case in 
point.  While there have been important advances in drug treatment for this disease (especially in the 
range of oral hypoglycemic drugs that are available), the promulgation of treatment guidelines and 
advances in patient self-management have likely also contributed to lowering death rates from the 
disease. 
 
Also on our list of suspected omitted variables is the distribution of health inputs across individuals.  
Specifically, all studies specify an aggregate health production function using inputs that might apply at 
the individual level.  Aggregate health, however, also depends on the distribution of inputs across 
individuals if the production function is non-linear.  To illustrate, suppose that a fixed amount of 
healthcare is divided among 2 individuals A and B, so that the average per capita allocation is constant, 
regardless of how it is divided.  Suppose further that the marginal productivity of healthcare declines, 
the more is used.  Then average population health depends on the allocations to A and B; if initially B 
gets all the healthcare, then average health can be improved by a small transfer from B to A – because 
health is a concave function of healthcare, the improvement in A’s health outweighs the decline in B’s 
health.  Estimates from both studies are suspect if changes in mean values of health care inputs are 




In addition to problems created by correlation between regressors and the error term, the LS estimator 
is also potentially adversely affected by non-stationarity of the regressors.   CMO claim that, because 
their GLS model is asymptotically equivalent to a regression on the first-differenced variables, their 
estimator is robust to the presence of non-stationary variables.  But it is not clear if this is the case.  
First, their sample size is modest so it is unclear if an asymptotic result would be a good approximation.  
Second, it is unclear if their model covariates are all integrated of the same order.  Lichtenberg cannot 
rule out the hypothesis that LE and real health care spending are random walks although he presents 
evidence that the annual NMEs approved is stationary. 
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Plausability of Estimates 
 
Granger (1999) argues that it is better to judge a model by its outputs, not inputs.  After all, it is unclear 
to what extent the criticisms leveled against a model matter empirically.  Hence, we assess the output of 
the empirical LE models – i.e. the marginal effects estimates and predictions.  We first ask whether the 
models’ estimates of pharmaceutical productivity are consistent with estimates obtained from other 
sources.  We could not locate any other sources of data on the LE gains of pharmaceutical R&D 
expenditure per se, but we did locate a review of the estimates of cost per ‘quality adjusted’ life year, or 
QALY, produced by 251 different pharmaceuticals introduced over the period 1976-1997 (Neuman et al, 
2000).  Presumably it is more costly to produce a quality adjusted life year (a year of life spent in normal 
health) than a life year spent in perhaps compromised health, so the estimates reviewed by Neuman 
might overestimate the cost per (unadjusted) LE.  On the other hand, the 251 different drugs Neuman 
reviewed might not be representative of all the 526 different drugs introduced into the US over the 
same period; in particular, these evaluations might be selected for formal evaluation and the results 
published due to particularly favorable cost effectiveness.  Moreover, the economic appraisals typically 
rely of efficacy estimates generated from clinical trials, and thus might overstate treatment 
effectiveness in routine clinical conditions.  On balance then, Neuman’s estimates likely serve as a useful 
benchmark. 
 
Neuman finds that the median cost per QALY produced by pharmaceuticals is US$ 11,000 (1998 dollars).  
How does this figure compare with the estimates produced by CMO?  CMO did not report directly 
comparable estimates but it is possible to generate comparable figures from the marginal effects 




𝗽𝑘×?𝐸                            (3) 
 
This expression gives the change in the input ∆𝑥𝑘 required to increase the LE measure by 1 year 
(∆?𝐸 = 1), given CMO’s elasticity estimate 𝗽𝑘, and the sample averages of 𝑥𝑘 and ?𝐸 (𝑥 𝑘 and ?𝐸     , 
respectively).  Estimates of ∆𝑥𝑘 for each of CMO’s 6 models (sex-specific models of LE at birth, LE at 65 
and infant mortality rates per 1000 births) are presented in Table 1.   
 
Table 1  Estimated change in real per capita health care spending required to increase health outcome 
by one unit, by type of health care spending.  Estimates based on CMO (2005).  
 
health outcome  sex  type of health care spending 











infant mortality rate per 1000 live births  male  -145  -89  -440 
   female  -153  -67  -1,111 
life expectancy at birth  male  182  97  1,468 
   female  419  109  22,932 
life expectancy at 65  male  256  201  -2,439 
   female  768  486  -8,175 7  
 
 
Hence CMO’s estimates, which are in the range $97 (the increase in RPC public drug spending required 
to increase male LE at birth by one year) to $768 (the increase in RPC private drug spending required to 
increase male LE at 65 by one year) are between 1% to 7% of Neuman et al’s median estimate of 
$11,000.
1  Shaw’s estimates – between $152 and $231 – are in the same ballpark as CMO’s.     
 
Frech and Miller’s estimates of drug spending on disability-adjusted LE are perhaps most directly 
comparable to Neuman’s because they explicitly account for the potential effects of drugs on morbidity.   
Frech and Miller’s estimates imply that an additional year of disability adjusted LE can be purchased for 
a figure in the range of $140 to $186. 
 
Table 2  Estimated change in real per capita health care spending required to increase health outcome 
by one unit, by type of health care spending.  Estimates based on Frech and Miller (2004).  
 
health outcome  sex  type of health care spending 




disability adjusted life expectancy at birth  male 
                   
186  1,012 
   female 
                   
173   940 
disability adjusted life expectancy at 60  male 
                   
172   2,534 
   female 
                   
140   2,059 
 
Lichtenberg provides estimates of the expenditure on pharmaceutical R&D and publicly financed 
healthcare required to increase LE by one year.  Evaluating his elasticity estimates at his sample means, 
in equilibrium, one additional year of LE at birth can be purchased for $171 in per capita public 
healthcare expenditure or just $16 in per capita outlays on pharmaceutical R&D.
 2  Our $171 estimate is 
a fraction of Lichtenberg’s estimate of $9,640 – the reason for the difference is that Lichtenberg 
assumes that only newborns would benefit from increased healthcare spending, while we assume that 
everyone benefits.  Our estimate is certainly too low and Lichtenberg’s too high, but we feel our 
estimate is closer to the truth.  The LE measure used in the literature is ‘period’ LE, which is a function of 
age-specific death rates for a given year.  If it were the case that healthcare affected just infant mortality 
rates then Lichtenberg’s approach would be correct.  But health care use tends to increase with age, 
suggesting that the benefit of healthcare use does as well.   
 
Another way of assessing the plausibility of the LE production models is to compare the out-of-sample 
forecasts from these models with actual values.  We therefore gathered post-sample data on the 
covariates used in the respective models (1999-2004 for CMO’s models, 2002-2004 for Lichtenberg’s 
                                                 
1 Interestingly, CMO find that non-drug spending has deleterious effects on the LE of those who have reached 65 
years of age: Every $2400 increase in RPC non-drug spending was found to decrease male LE at 65 by one year. 
2 This $16 estimate uses Lichtenberg’s assumptions re: the cost of developing a new drug – $500 million – and the 
average size of the US population – 224 million – during his sample period.    8  
 
model #3, and 1985-1993 and 1980-1988 for the covariates in Shaw’s models), and using these data, 
forecasted values of the outcome variables.  Because the models are log-linear, we compared post-
sample forecasted growth rates in the outcome variable with actual growth rates.   
 
The prediction performance of CMO’s models varied depending on the outcome being modeled (Table 
3).  Life expectancy at birth was predicted with the greatest degree of accuracy; forecast errors were 
between 21%-50% of observed LE growth   Life expectancy at 65 was less well predicted – forecast 
errors were between 85%-139% of observed values.  Female LE was predicted to decline when it 
actually grew.  The infant mortality models performed worst; the models predicted reductions in the 
order of 33% and 21% for males and females, respectively, while male IMRs declined by 4% and females 
actually increased by 4%.  Lichtenberg’s model fared better.  It over-predicted the 0.71% growth in LE 
observed 2001-2004 but the prediction error was only 10% of observed growth. 
 
 
Table 3 Observed and predicted growth in life expectancy and infant mortality in Canada, 1998-2004 
 











Life expectancy at birth 
         
 
Males  2.37%  1.87%  0.50%  21% 
 
Females  1.35%  0.67%  0.68%  50% 
Life expectancy at 65 
         
 
Males  8.59%  1.27%  7.32%  85% 
 
Females  4.48%  -1.76%  6.24%  139% 
Infant mortality rate 
         
 
Males  -3.51%  -33.14%  29.63%  -844% 
 
Females  4.17%  -20.85%  25.01%  600% 
 
Notes 







where 𝑘 indices the covariates used in CMO’s models, and ?𝑘 indicates the estimated elasticity 
associated with the 𝑘th covariate.   
 
Shaw’s models produced forecasts errors in the order of 11.7% of observed growth of female LE at age 
40 to 27.2% of observed growth of male LE at age 40.  Forecast errors for the models of LE at 65 were 
about 15% of observed growth. 
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Do the marginal productivity estimates stand up to alternative model 
specifications? 
 
A model is more credible if its outputs are robust to seemingly innocuous changes in its specification.  
We therefore assembled the data used in the CMO, Shaw and Lichtenberg studies, updated them where 




We estimated modified versions of CMO’s models using province and year level data over the period 
1981-2004.  We modified their model in three ways.  First, instead of using contemporaneous values of 
covariates, we used one period lags of on RPC spending on pharmaceuticals, hospitals, physicians, a 
composite of all other health care spending, and RPC GDP.  Second, we used province-specific dummies 
to control for time-invariant provincial differences in the outcome variables; CMO used regional 
dummies.  Third, we used year dummies to control for the influence of time-varying confounders.  This 
approach avoids the problems associated with identifying, measuring and modeling the impact of time-
varying confounder variables.  Specifically, one would likely miss important determinants; moreover, the 
factors that one might attempt to control for explicitly – alcohol and cigarette consumption, for instance 
– are likely mismeasured.  The assumption underlying our approach – common year effects – strikes us 
as being defensible for the case of medical technology, which Cutler et al suggest as being the primary 
driver of recent LE gains.  Presumably medical technology is equally accessible in all the provinces.  This 
assumption is perhaps less defensible for the case of the distribution of alcohol, cigarette consumption 
and other lifestyle factors – the distribution of these factors could evolve differently in the different 
provinces.  We therefore estimate alternative models that control for time-varying confounders using 
province-specific quadratic time trends.   
 
The revised models yield dramatically different estimates of the expenditure required to increase LE by 
one year or increase infant mortality rates by one death per 1,000 live births.  The models estimated 
using year dummies indicate that drug spending increases infant mortality rates.  Drug spending is still 
found to increase LE, but the expenditure required to extend LE by 1 year is now much greater than that 
implied by CMO.  Indeed expenditure requirements are between 5 and 72 times larger than 
corresponding estimates from CMO’s models.  The model that uses province-specific quadratic time 
trends produces estimates in the range of 10 and 527 times those produced by CMO.   This model 
suggests, however, that drug spending reduces infant mortality rates. 
 
Table 4  Estimated change in real per capita health care spending required to increase health outcome 
by one unit, by type of health care spending.   Time varying confounders controlled for using year 
dummy variables. 
 
health outcome  sex  type of health care spending 






Hospitals  Physician 
services 
infant mortality rate per 1000 live births  Male  1,607  649  -1,357  930 
   female  1,044  280  -1,389  783 
life expectancy at birth  Male  10,086  6,726  32,422  -5,222 10  
 
health outcome  sex  type of health care spending 






Hospitals  Physician 
services 
   female  22,021  7,861  57,377  -7,120 
life expectancy at 65  male  3,455  1,831  16,358  -1,781 
   female  4,720  2,233  57,175  -3,467 
 
Note:  cost estimates obtained by evaluating elasticity estimates at sample means.  GLS estimator used 
to allow for province-specific heteroskedasticity and common AR(1) errors. 
  
Table 5  Estimated change in real per capita health care spending required to increase health outcome 
by one unit, by type of health care spending.   Time varying confounders controlled for using province 
specific quadratic time trends. 
 
health outcome  Sex  type of health care spending 






hospitals  Physician 
services 
infant mortality rate per 1000 live births  Male  -3,425  -227  22,945  1,368 
   Female  -2,582  -323  -9,558  2,524 
life expectancy at birth  Male  96,061  4,974  23,285  -7,217 
   Female  164,769  4,384  20,730  -18,149 
life expectancy at 65  Male  5,733  6,442  10,856  -6,717 
   Female  29,059  4,883  7,955  -9,477 
 
Note:  cost estimates obtained by evaluating elasticity estimates at sample means.  GLS estimator used 




Whereas Shaw estimated his models using a cross section of 19 OECD countries in 1997, we used panel 
data on the LE of selected OECD countries (Australia, Belgium, Canada, Denmark, Finland, France, 
Germany, Ireland, Japan, Netherlands, New Zealand, Norway, Sweden, UK, US) over the period 1962-
2004.  The primary advantage of our approach, of course, is that we can control for time-invariant 
country-specific differences in LE through the use of country dummy variables.  The second advantage is 
sample size – we estimated parameters using as many as 370 observations; Shaw had just 19 
observations to work with.  We used lagged values of the same covariates that Shaw used, but we 
considered various lag lengths.   Shaw used a 15 year lag; we tried 15 years and shorter lags (of 1, 2, 3, 4, 
and 5 years) as well. Finally, we considered models with and without year dummies included to assess 
the robustness of the estimates to the presence of time-varying confounders. 
 
Our OLS estimates, appearing in Appendix 1 and 2, imply completely different values of pharmaceutical 
productivity compared to those implied by Shaw.  Regardless of the covariate lag length chosen or the 
inclusion of year dummies, the models suggest that pharmaceutical spending shortens LE.  




Recall that Lichtenberg regressed LE on its lagged value, current and lagged values of the number of 
NMEs approved and lagged RPC public healthcare spending.  (All variables were in log units.)  Clearly 
NME approvals do not affect LE directly; they affect LE only to the extent that they are consumed.  
Lichtenberg’s model can thus be interpreted as a reduced form of a ‘structural’ model in which LE 
depends on drug consumption and drug consumption depends on the number of NMEs approved.  
When viewed from this perspective, Lichtenberg’s model specification should be adjusted slightly.  In 
particular, the health care spending variable he uses should reflect non-pharmaceutical health care 
spending since drug spending would not appear in a reduced form model.  We therefore re-estimated 
Lichtenberg’s model with two modifications.  First, we used up-to-date data (data were collected for the 
period 1960-2004).  Second, we replaced lagged RPC public healthcare spending with lagged RPC total 
spending on hospitals, physicians, and public health.  Estimates were obtained using generalized least 
squares allowing for AR(1) errors; given the modest sample size we included the Prais-Winsten 
transformed first observation.  Using these estimates, which appear in Appendix 3, we determined the 
expenditure on the various types of health care required to increase LE at birth by one year in long run 
equilibrium.  We also determined the number of NMEs required to accomplish the same thing.  We 
computed the per capita cost of developing the requisite number of NMEs by multiplying the estimate 
by $500M (the average cost per NME) and dividing by the average size of the US population during the 
sample period, 225M. 
 
Table 6  Estimated change in real per capita spending required to increase LE at birth by one year, in 
longrun equilibrium, by type of intervention. 
 
Intervention  per capita cost to 
increase LE by one 
year 
develop NME  526.24 
expenditures on public health  0.03 
expenditures on physicians  -1386.26 
expenditures on hospitals  -5215.51 
 
The estimates indicate that the per capita outlays of $526 on drug development are required to increase 
LE at birth by one year.  This estimate is substantially more than the $16 estimate derived from 
Lichtenberg’s model but it is nonetheless still less than consensus estimates of the value of a life year.  
According to the model, an even less expensive option would be to invest in public health; an expected 
life year can be acquired for only $0.03.  The model suggests that spending on physicians and hospitals is 





New pharmaceutical drugs have undoubtedly contributed to the marked increases in LE observed over 
the last 50 years; the question is how much have they contributed?  We argue that it is difficult to 
resolve this question using aggregate data.  There are several hurdles, including disentangling the  
contribution of new drugs from advances in disease management, changes in the distribution of health 12  
 
care and other confounding factors; measuring drug inputs using inflation-adjusted drug spending data; 
and dealing with non-stationary time series data.  While it is unclear to what extent these modeling 
issues matter empirically, we present evidence that the several empirical models that have attempted to 
identify the contribution of pharmaceuticals to LE are not plausible.   
 
These models assess the partial correlations between drug use or new drug launches and LE using cross 
sections of OECD countries, province-year level data and annual data for the US.  We are skeptical of 
these models for several reasons.  First, these studies produce estimates of pharmaceutical productivity 
that we feel are implausibly high.  One study implies that a year of disability-adjusted LE at birth can be 
purchased for under US$ 200.  Cost effectiveness studies of individual drugs, by contrast, indicate that 
the median cost of a quality-adjusted life year is in the order of US$ 11,000.  Second, some of the 
models estimated using province-year level LE data have very large forecast errors.  Third, the models 
that we replicated were found to be sensitive to seemingly innocuous changes in specification.   The 
model we estimated using province-year level LE data for Canada suggests that pharmaceuticals are 
indeed productive, but not as productive as implied in the literature.   Our estimates of the increase in 
per capita pharmaceutical expenditure needed to increase LE by one year is in the range $1,800 to 
$22,000; the original study implied estimates in the range $97 to $768.   Another model estimated using 
LE of a cross-section of OECD countries found drugs to be highly effective.  However, when we re-
estimated the model exploiting within-country variation in drug expenditure we reached the opposite 
conclusion.  This suggests that among OECD countries, drug spending is correlated with some 
unobserved determinant of LE.  Finally, we found that modeling annual US LE using categories of 
healthcare spending (instead of an aggregate of all healthcare spending) produced drastically different 
policy implications.  The original study found that new drug introductions were markedly more cost 
effective than public health care spending.  We found just the opposite – indeed per capita outlays on 
public health measures in the order of $0.03 were found to increase LE by one year. 
 
The conclusion that we draw from these analyses is that it is difficult to estimate the bio-medical 
determinants of LE using aggregate data.  Analyses using individual level data or perhaps disease specific 
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Appendix 1: Shaw’s models estimated using panel OECD data.  Results for Male life expectancy 
 
legend: * p<0.05; ** p<0.01; *** p<0.001 
   
Model specification  Males 
Covariates lagged:  Year fixed 
effects 
included? 
LE at 40  LE at 60  LE at 65 
PHARM  HEALTH  PHARM  HEALTH  PHARM  HEALTH 
1 yr  2 yrs  3 yrs  4 yrs  5 yrs  16 y  coef.  signif.  coef.  signif.  coef.  signif.  coef.  signif.  coef.  signif.  coef.  signif. 
x                 x  -0.048  ***  0.006       -0.073  ***  0.022  *    -0.077  ***  0.018      
x                    -0.022  ***  -0.041  ***  -0.029  ***  -0.056  ***  -0.030  ***  -0.058  *** 
   x              x  -0.046  ***  0.007       -0.072  ***  0.023  *    -0.073  **   0.019      
   x                 -0.022  ***  -0.037  ***  -0.028  ***  -0.053  ***  -0.027  **   -0.058  *** 
      x           x  -0.047  ***  0.004       -0.074  ***  0.018       -0.075  ***  0.011      
      x              -0.023  ***  -0.039  ***  -0.029  ***  -0.061  ***  -0.026  **   -0.070  *** 
         x        x  -0.047  ***  0.004       -0.075  ***  0.019       -0.075  ***  0.010      
         x           -0.019  ***  -0.040  ***  -0.024  **   -0.060  ***  -0.021  *    -0.072  *** 
            x     x  -0.042  ***  -0.001       -0.067  **   0.012       -0.066  ***  0.006      
            x        -0.018  ***  -0.039  ***  -0.021  **   -0.060  ***  -0.018  *    -0.068  *** 
               x  x  -0.010  *    -0.001       -0.018  *    -0.004       -0.023  **   -0.002      
               x     -0.009       -0.021  **   -0.016       -0.050  ***  -0.021  *    -0.056  *** 15  
 
Appendix 2: Shaw’s models estimated using panel OECD data.  Results for Female life expectancy 
 
Model specification  Females 
Covariates lagged:  Year fixed 
effects 
included? 
LE at 40  LE at 60  LE at 65 
PHARM  HEALTH  PHARM  HEALTH  PHARM  HEALTH 
1 yr  2 yrs  3 yrs  4 yrs  5 yrs  16 y  coef.  signif.  coef.  signif.  coef.  signif.  coef.  signif.  coef.  signif.  coef.  signif. 
x                 x  -0.037  ***  0.005     -0.051  ***  0.013     -0.049  ***  0.007    
x                    -0.027  ***  -0.004     -0.036  ***  -0.004     -0.034  ***  -0.004    
   x              x  -0.035  ***  0.006     -0.048  ***  0.013     -0.042  ***  0.002    
   x                 -0.025  ***  -0.002     -0.032  ***  -0.001     -0.028  ***  -0.004    
      x           x  -0.036  ***  0.002     -0.050  ***  0.008     -0.044  ***  -0.008    
      x              -0.024  ***  -0.007     -0.030  ***  -0.012     -0.025  **   -0.020    
         x        x  -0.036  ***  0.002     -0.050  ***  0.009     -0.048  ***  -0.003    
         x           -0.019  ***  -0.009     -0.022  **   -0.016     -0.018  *    -0.023    
            x     x  -0.031  ***  0.001     -0.043  ***  0.010     -0.038  ***  0.003    
            x        -0.016  ***  -0.010     -0.017  *    -0.016     -0.012       -0.018    
               x  x  -0.014  **   0.002     -0.023  **   0.016     -0.024  *    0.011    
               x     -0.011  *    -0.014     -0.016       -0.021     -0.015       -0.028  *  
 
legend: * p<0.05; ** p<0.01; *** p<0.001 
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Appendix 3  Estimated reduced form model of LE at birth based on annual US data 1960-2004. 
 
Covariate  estimate 
Lag log real per capita expenditure on physicians  -0.010 
   -1.650 
Lag log real per capita expenditure on hospitals  -0.005 
   -1.170 
Lag log real per capita expenditure on public health  0.021 
   3.420 
Lag log life expectancy at birth  0.800 
   15.390 
Lag log number of new molecular entities approved  0.0005 
   0.400 
Log number of new molecular entities approved  0.004 
   3.320 
Constant  0.857 
   3.970 
Rho  -0.090 
N  44 
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